logo

Insys Therapeutics, Inc. (INSY)



Trade INSY now with
  Date
  Headline
2/25/2019 6:12:37 AM INSYS Presents Poster Of Initial PK Study Of Comparative Bioavailability Of Epinephrine Nasal Spray And EpiPen
1/9/2019 6:04:34 AM INSYS Therapeutics Announces Results Of Dose-Finding PK Study For Epinephrine Nasal Spray For Treatment Of Anaphylaxis
12/18/2018 6:03:11 AM INSYS Therapeutics Announces Participation At FDA Advisory Committee Meeting Addressing The Co-Prescribing Of Naloxone
12/4/2018 6:04:48 AM INSYS Therapeutics Presents New Clinical Data From Long-Term Safety Study Of CBD Oral Solution
11/1/2018 6:15:25 AM INSYS Therapeutics Says PK Study Of Proprietary Intranasal Naloxone Spray Formulations Showed Distinctive PK Profile
10/10/2018 6:04:09 AM INSYS Therapeutics Adds Mark Nance To Its Senior Management Team As Chief Legal Officer And General Counsel
10/1/2018 6:06:09 AM INSYS Therapeutics Signs Definitive License Deal With Lunatus To Commercialize SUBSYS In Middle East
9/24/2018 6:04:23 AM INSYS Therapeutics Completes Initial Clinical Study Of Dronabinol Inhalation With Innovative Breath-Actuated Inhaler
9/4/2018 6:09:20 AM INSYS And UC San Diego’s Center For Medicinal Cannabis Research Expand Collaboration
8/30/2018 6:04:19 AM INSYS Says FDA Grants Fast Track Designation For Epinephrine Nasal Spray As Investigational Treatment For Anaphylaxis
8/8/2018 7:04:52 AM INSYS Therapeutics Reaches Agreement In Principle To Settle Department Of Justice Investigation